Goldman Sachs analyst Corinne Jenkins maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price target from $77 to $74.
Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $74
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.